Skip to main content

#162306

Glioblastoma WHO IV NCH82 cell line

Cat. #162306

Glioblastoma WHO IV NCH82 cell line

Cat. #: 162306

Organism: Human

Tissue: Brain

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Christel Herold-Mende

Institute: Heidelberg University

Primary Citation: Karcher et al. 2005. Cancer Cell Biol. 118(9):2182-2189. PMID: 16331629.

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Glioblastoma WHO IV NCH82 cell line
  • Cancer: Brain
  • Organism: Human
  • Tissue: Brain
  • Growth properties: Mixed - adherent and suspension
  • Description: Glioblastoma WHO IV cell line, NCH82
  • Biosafety level: 2

Handling

  • Growth medium: DMEM supplemented with 10% fetal calf serum + 1% penicillin/streptomycin
  • Temperature: 37°C
  • Atmosphere: 5% CO2

References

  • Arseni et al. 2023. Cancers. 15(2):479. PMID: 36672428.
  • Fermi et al. 2022. Chemistry. 28(34):e202104535. PMID: 35293640.
  • Wirthschaft et al. 2019. Acta Neuropathol. 138(2):275-293. PMID: 31062076.
  • Jortzik et al. 2014. Biochimica et Biophysica Acta. 1844(8):1415-1426. PMID: 24440405.
  • Schüle et al. 2012. Scientific World Journal. 2012:697313. PMID: 22919349.
  • Dokic et al. 2012. Glia. 60(11):1785-1800. PMID: 22951908.
  • Campos et al. 2011. Am J Pathol. 178(5):1953-1964. PMID: 21514413.
  • Konkarevic et al. 2009. Free Radic Biol Med. 46(8):1096-108. PMID: 19439228.
  • Siegelin et al. 2008. Mol Cancer Ther. 7(11):3566-3574, PMID: 19001439.
  • Gdynia et al. 2007. Mol Cancer Res. 5(12):1232-1240. PMID: 18171980.
  • Karcher et al. 2005. Cancer Cell Biol. 118(9):2182-2189. PMID: 16331629.
  • Steiner et al. 2004. J Neurooncol. 66(1-2):129-138. PMID: 15015778.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.